Accelerate Diagnostics Income Statement - Quarterly (NASDAQ:AXDX)

Add to My Stocks
$24.45 $0.25 (1.03%) AXDX stock closing price Feb 22, 2017 (Closing)

Fundamental analysis of AXDX stock involves analyzing its financial statements, apart from checking the Accelerate Diagnostics stock price In the income statement, an investor can check for important parameters like the topline, the bottomline, the EPS basic, dividends etc. Investors typically check YoY or QoQ revenue growth. 2016-Q3 revenue is $0.02M and has increased from $0.02M quarter on quarter as is evident when you compare the latest figures in the latest Accelerate Diagnostics profit and loss statement with those of the prior corresponding period. (See also:Accelerate Diagnostics assets and Accelerate Diagnostics free cash flow) View details of revenue and profits for Accelerate Diagnostics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2
Accelerate Diagnostics Net Sales or Revenues
0.02M0.02M0.16M0.02M0.09M0.02M0.01M0.08M0.02M0.01M
Cost Of Goods Sold (COGS)----------
Accelerate Diagnostics Gross Profit
0.02M0.02M0.16M0.03M0.09M0.01M0.01M0.09M0.01M0.01M
Research & Development Expense7.53M8.06M7.35M6.04M6.49M7.12M6.37M5.99M5.94M4.56M
Selling General & Admin Expense9.3M9.23M7.43M5.94M4.33M4.75M2.86M2.59M2.62M3.44M
Income Before Depreciation Depletion Amortization-16.81M-17.28M-14.62M-11.93M-10.73M-11.86M-9.23M-8.49M-8.55M-7.99M
Depreciation Depletion Amortization0.6M0.6M0.54M0.61M0.46M0.4M0.32M0.32M0.26M0.16M
Non Operating Income0.11M0.02M0.09M0.03M0.02M0.01M0.01M0.03M0.01M0.01M
Interest Expense---0.02M---0.01M--
Accelerate Diagnostics Pretax Income
-17.29M-17.86M-15.07M-12.52M-11.18M-12.25M-9.54M-8.78M-8.81M-8.15M
Provision for Income Taxes---0.64M---0.64M---
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-17.3M-17.87M-15.07M-13.16M-11.82M-12.25M-8.9M-8.77M-8.81M-8.15M
Extraordinary Items & Discontinued Operations----------
Accelerate Diagnostics Net Income (Profit/Loss)
-17.3M-17.87M-15.07M-13.16M-11.82M-12.25M-8.9M-8.77M-8.81M-8.15M
Average Shares used to compute Diluted EPS51.24M51.21M51.2M45M44.73M44.68M44.65M43.83M44.58M43.48M
Average Shares used to compute Basic EPS51.24M51.21M51.2M45M44.73M44.68M44.65M43.83M44.58M43.48M
Income Before Nonrecurring Items-17.3M-17.87M-15.07M-13.16M-11.82M-12.25M-8.9M-8.77M-8.81M-8.15M
Income from Nonrecurring Items----------
Accelerate Diagnostics Earnings Per Share Basic Net
-0.34-0.35-0.29-0.29-0.25-0.27-0.20-0.20-0.20-0.19
Accelerate Diagnostics Earnings Per Share Diluted Net
-0.34-0.35-0.29-0.29-0.25-0.27-0.20-0.20-0.20-0.19
EPS Diluted Before Nonrecurring Items-0.34-0.35-0.29-0.29-0.25-0.27-0.20-0.20-0.20-0.19
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:25
AXDX
It is very helpful to read a report on Accelerate Diagnostics stock analysis. An investor must check the following items in an income statement:
  • Topline: A growing topline, as seen from the Accelerate Diagnostics revenue chart, as is the case with Accelerate Diagnostics indicates a growing business. One needs to compare the QoQ or YoY topline growth of AXDX stock with its peers like INGN stock and CYNO stock to see if the growth compares well with what can be expected for a company in that industry.
  • Bottom line: Most businesses like Accelerate Diagnostics try to improve their bottom line by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.
The income statement is also called statement of revenue and expense. The financials along with Accelerate Diagnostics historical stock prices provides a lot of details about the firm. .

Accelerate Diagnostics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
5694.6273
Operating margin
-87050
Net profit margin
-86500
Dividend yield
0%